BioSpace News Archive

A donation from leading temperature control packaging company Softbox Systems has enabled the charity International Health Partners to deliver cold-chain oncology medicines, giving children in Tanzania the chance to recover from cancer.

At the Drug Development Unit at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust in London, the first patient in Phoenix’s first in human “ACTivate Trial” has received ACT® in combination with chemotherapy for treatment of hepatic metastases associated with colorectal and pancreatic cancer.

The GOOD DESIGN Awards is the oldest and most prestigious global awards program for design excellence and design innovation.

Shares of Minerva Neurosciences are down more than 22% in premarket trading after the company announced late Wednesday that its Phase IIb major depressive disorder (MDD) trial failed to meet primary and key secondary endpoints.

What they found was that melanoma cells are more likely to metastasize through the body if their cells have high concentrations of MCT1 on their cell surface.

The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional novel product candidates based on Turnstone’s vaccinia virus platform for future independent development.

Xenikos B.V. announced that the first patient has been treated in their U.S.-based Phase 3 registration trial designed to evaluate the use of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.

Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.

The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.

The company will utilize their new headquarters for more efficient distribution and expanded capabilities